State Street Corp Buys 264 Shares of Sanofi (NASDAQ:SNY)

State Street Corp increased its position in shares of Sanofi (NASDAQ:SNY) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,734 shares of the company’s stock after purchasing an additional 264 shares during the quarter. State Street Corp’s holdings in Sanofi were worth $3,270,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at approximately $29,000. Concord Wealth Partners boosted its holdings in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Sanofi during the 2nd quarter worth $51,000. Finally, UMB Bank n.a. increased its holdings in Sanofi by 39.2% in the 3rd quarter. UMB Bank n.a. now owns 1,073 shares of the company’s stock worth $62,000 after purchasing an additional 302 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 1.0 %

Sanofi stock opened at $48.23 on Tuesday. The firm has a 50 day moving average price of $49.64 and a two-hundred day moving average price of $52.03. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The firm has a market cap of $122.40 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.55 EPS. Equities analysts predict that Sanofi will post 4.06 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SNY shares. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.